Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer.
Prostate carcinoma is the most commonly associated with osseous metastases malignancy in males. The lesions, being usually of a mixed sclerotic/lytic variety and less often of the pure sclerotic type, need to be treated by a bone seeking radioactive element with an as low as possible radiobiological burden on the surrounding (peritumoral) tissues. Rhenium-186-HEDP was used to treat these osseous metastatic lesions due to its bone seeking kinetics attractive radiochemical properties. Of a total of 16 prostate cancer patients. 3 experiment loss of pain, 8 experienced obvious and 2 some improvement. No change was observed in 3 patients. Ten patients manifested a flare syndrome increasing pain approximately 2 to 6 days, after Re-186-HEDP i.v. application. Six patients showed a definite and 9 a slight decrease in platelet levels and absolute number of polymorphonuclear white blood cells, up to fourth week following treatment. One patient underwent a whole blood transfusion and in 2 peripheral neuropathy was observed lasting about 9 to 12 days. Re-186-HEDP appears to be a promising new metal ion complex for the palliation of painful bone metastases in prostate cancer. Compared to Sr-89 therapy, it shows a longer analgetic efficacy and has the advantage of emitting gamma rays, a fact which facilitates dosimetric calculations.
Limouris
G
G
Radiology Department, Areteion Hospital, Athens University Medical Faculty, Greece.
Shukla
S K
SK
Manetou
A
A
Kouvaris
I
I
Plataniotis
G
G
Triantafyllou
N
N
Rigas
A V
AV
Vlahos
L
L
D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000532:radiotherapy* / Q000556:secondary*; D012968:Etidronic Acid / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009942:Organometallic Compounds; D010147:Pain Measurement; D010148:Intractable Pain; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology / Q000532:radiotherapy*; D011868:Radioisotopes; D011877:Radionuclide Imaging; D012211:Rhenium / Q000627:therapeutic use*; D013669:Technetium Tc 99m Medronate
D009942:Organometallic Compounds; D011868:Radioisotopes; C101598:rhenium-186 HEDP; D012211:Rhenium; D012968:Etidronic Acid; D013669:Technetium Tc 99m Medronate